Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
Loading...
Embargo End Date
ICR Authors
Authors
Tong, D
Chisholm, J
Madden, B
Ahmed, M
Chisholm, J
Madden, B
Ahmed, M
Document Type
Journal Article
Date
2024-04-10
Date Accepted
2024-02-23
Abstract
BACKGROUND: Pulmonary inflammatory myofibroblastic tumour (IMT) is a rare condition that usually presents in young individuals and is associated with anaplastic lymphoma kinase (ALK)-translocation. CASE PRESENTATION: We report a case of an 18-year-old Caucasian man with ALK-translocated pulmonary IMT treated with multimodality therapy. The patient presented with breathlessness and was found to have a collapsed left lung. Further investigations revealed an ALK-translocated pulmonary IMT. This is usually treated with an ALK-inhibitor but patient declined after discussing potential side-effects and had repeated rigid bronchoscopic interventions for local disease control. Due to persistent local recurrence, patient received radical external beam radiotherapy (EBRT) with pulse steroids, and one year later started on Ibuprofen, a non-steroidal anti-inflammatory agent (NSAID). Following multimodality treatment, he developed a complete response. He remains treatment-free for the past seven years. Eleven years on from his diagnosis, he remains in remission with a ECOG performance status of zero. CONCLUSIONS: Achieving long-term local control in pulmonary IMT can be challenging. Multimodality treatment is sometimes needed but the overall outlook remains good.
Citation
Journal of Medical Case Reports, 2024, 18 (1), pp. 167 -
Source Title
Journal of Medical Case Reports
Publisher
BMC
ISSN
1752-1947
eISSN
1752-1947